Annual CFF
$53.17 M
-$76.47 M-58.99%
December 31, 2023
Summary
- As of February 7, 2025, EWTX annual cash flow from financing activities is $53.17 million, with the most recent change of -$76.47 million (-58.99%) on December 31, 2023.
- During the last 3 years, EWTX annual CFF has fallen by -$67.11 million (-55.80%).
- EWTX annual CFF is now -71.48% below its all-time high of $186.38 million, reached on December 31, 2021.
Performance
EWTX Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly CFF
$3.33 M
+$1.38 M+70.75%
September 30, 2024
Summary
- As of February 7, 2025, EWTX quarterly cash flow from financing activities is $3.33 million, with the most recent change of +$1.38 million (+70.75%) on September 30, 2024.
- Over the past year, EWTX quarterly CFF has increased by +$3.54 million (+1679.62%).
- EWTX quarterly CFF is now -98.62% below its all-time high of $241.07 million, reached on March 31, 2024.
Performance
EWTX Quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM CFF
$299.35 M
+$3.54 M+1.20%
September 30, 2024
Summary
- As of February 7, 2025, EWTX TTM cash flow from financing activities is $299.35 million, with the most recent change of +$3.54 million (+1.20%) on September 30, 2024.
- Over the past year, EWTX TTM CFF has increased by +$299.47 million (+241507.26%).
- EWTX TTM CFF is now -2.57% below its all-time high of $307.23 million, reached on March 31, 2021.
Performance
EWTX TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash From Financing Formula
CFF = Cash Inflows from Financing Activities − Cash Outflows from Financing Activities
EWTX Cash From Financing Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -59.0% | +1679.6% | +10000.0% |
| 3 y3 years | -55.8% | +1679.6% | +10000.0% |
| 5 y5 years | +114.4% | +1679.6% | +10000.0% |
EWTX Cash From Financing Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -71.5% | at low | -98.6% | +1200.0% | at high | >+9999.0% |
| 5 y | 5-year | -71.5% | +114.4% | -98.6% | +472.0% | -2.6% | >+9999.0% |
| alltime | all time | -71.5% | +114.4% | -98.6% | +472.0% | -2.6% | >+9999.0% |
Edgewise Therapeutics Cash From Financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | $3.33 M(+70.7%) | $299.35 M(+1.2%) |
| Jun 2024 | - | $1.95 M(-99.2%) | $295.80 M(+0.5%) |
| Mar 2024 | - | $241.07 M(+355.0%) | $294.22 M(+453.4%) |
| Dec 2023 | $53.17 M(-59.0%) | $52.99 M(<-9900.0%) | $53.17 M(<-9900.0%) |
| Sep 2023 | - | -$211.00 K(-157.2%) | -$124.00 K(-100.1%) |
| Jun 2023 | - | $369.00 K(+1657.1%) | $129.78 M(+0.1%) |
| Mar 2023 | - | $21.00 K(-106.9%) | $129.59 M(-0.0%) |
| Dec 2022 | $129.64 M | -$303.00 K(-100.2%) | $129.64 M(-0.5%) |
| Sep 2022 | - | $129.69 M(>+9900.0%) | $130.24 M(>+9900.0%) |
| Jun 2022 | - | $179.00 K(+145.2%) | $582.00 K(-218.1%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2022 | - | $73.00 K(-75.1%) | -$493.00 K(-100.3%) |
| Dec 2021 | $186.38 M(+55.0%) | $293.00 K(+691.9%) | $186.38 M(-33.7%) |
| Sep 2021 | - | $37.00 K(-104.1%) | $281.09 M(-8.2%) |
| Jun 2021 | - | -$896.00 K(-100.5%) | $306.20 M(-0.3%) |
| Mar 2021 | - | $186.95 M(+96.8%) | $307.23 M(+155.4%) |
| Dec 2020 | $120.28 M(+385.0%) | $95.00 M(+277.9%) | $120.28 M(+375.8%) |
| Sep 2020 | - | $25.14 M(>+9900.0%) | $25.28 M(>+9900.0%) |
| Jun 2020 | - | $135.00 K(>+9900.0%) | $135.00 K(>+9900.0%) |
| Mar 2020 | - | $0.00 | $0.00 |
| Dec 2019 | $24.80 M | - | - |
FAQ
- What is Edgewise Therapeutics annual cash flow from financing activities?
- What is the all time high annual CFF for Edgewise Therapeutics?
- What is Edgewise Therapeutics annual CFF year-on-year change?
- What is Edgewise Therapeutics quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for Edgewise Therapeutics?
- What is Edgewise Therapeutics quarterly CFF year-on-year change?
- What is Edgewise Therapeutics TTM cash flow from financing activities?
- What is the all time high TTM CFF for Edgewise Therapeutics?
- What is Edgewise Therapeutics TTM CFF year-on-year change?
What is Edgewise Therapeutics annual cash flow from financing activities?
The current annual CFF of EWTX is $53.17 M
What is the all time high annual CFF for Edgewise Therapeutics?
Edgewise Therapeutics all-time high annual cash flow from financing activities is $186.38 M
What is Edgewise Therapeutics annual CFF year-on-year change?
Over the past year, EWTX annual cash flow from financing activities has changed by -$76.47 M (-58.99%)
What is Edgewise Therapeutics quarterly cash flow from financing activities?
The current quarterly CFF of EWTX is $3.33 M
What is the all time high quarterly CFF for Edgewise Therapeutics?
Edgewise Therapeutics all-time high quarterly cash flow from financing activities is $241.07 M
What is Edgewise Therapeutics quarterly CFF year-on-year change?
Over the past year, EWTX quarterly cash flow from financing activities has changed by +$3.54 M (+1679.62%)
What is Edgewise Therapeutics TTM cash flow from financing activities?
The current TTM CFF of EWTX is $299.35 M
What is the all time high TTM CFF for Edgewise Therapeutics?
Edgewise Therapeutics all-time high TTM cash flow from financing activities is $307.23 M
What is Edgewise Therapeutics TTM CFF year-on-year change?
Over the past year, EWTX TTM cash flow from financing activities has changed by +$299.47 M (+241507.26%)